

Appl. No. 09/954,792 Amdt. dated April 23, 2004 Reply to Office action of October 23, 2003

REMARKS/ARGUMENTS

Claims 1-20 remain in this application.

Claims 1-12 and 14-20 have been withdrawn as the result of the instant restriction requirement.

In view of the Examiner's restriction requirement, applicant retains the right to present claims 1-12 and 14-20 in a divisional application.

Restriction

Restriction to one of the following inventions has been required under 35 USC 121:

I. Claims 1-2, drawn to a diagnostic marker, classified in class 530, subclass 380, for example.

II. Claims 3-6, drawn to a test kit, classified in class 422, subclass 58, for example.

III. Claims 7-10, drawn to a method for Schwann cell analysis, classified in class 435, subclass 7.1, for example.

IV. Claim 11, drawn to a test kit for having antibody to GFAP, classified in class 436, subclass 536, for example.

V. Claim 12, drawn to an anti-GFAP IgG, classified in class 530, subclass 387.1, for example.

VI. Claim 13, drawn to prediabetic screening assay, classified in class 435, subclass 7.92, for example.

Appl. No. 09/954,792 Amdt. dated April 23, 2004 Reply to Office action of October 23, 2003

VII. Claims 14-15 and 20, drawn to a method for treating a disease process, classified in class 424, subclass 184.1, for example.


VIII. Claims 16-19, drawn to screening assay, classified in class 530, subclass 412, for example.

Applicants hereby elect, without traverse the Group V invention comprised of claim 13.

SUMMARY

Now that applicants have fully responded to the Office Action mailed on October 23, 2003, an examination on the merits is respectfully requested.

Respectfully submitted,



Ferris H. Lander
Registration # 43,377

McHale & Slavin, P.A.
2855 PGA Boulevard
Palm Beach Gardens, FL 33410
(561) 625-6575 (Voice)
(561) 625-6572 (Fax)

\\Fs3\CLIENT FILES\2100-2199\2132 -Syn-X\2132_000074 - Diag. and Treatment of Early Diab\Amendments\2132.074 Resp to BR 10-23-03.vpd